psychedelicalpha.com

Norway approves public funding for generic ketamine to treat treatment-resistant depression. The announcement focuses on expanding access to ketamine by using a generic version, aiming to reduce barriers for patients who do not respond to standard antidepressant care. The development is positioned as a policy and health-system step that could increase availability of ketamine in clinical settings, especially where treatment-resistant depression remains difficult to manage.